Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis.

Alton EW, Beekman JM, Boyd AC, Brand J, Carlon MS, Connolly MM, Chan M, Conlon S, Davidson HE, Davies JC, Davies LA, Dekkers JF, Doherty A, Gea-Sorli S, Gill DR, Griesenbach U, Hasegawa M, Higgins TE, Hironaka T, Hyndman L, McLachlan G, Inoue M, Hyde SC, Innes JA, Maher TM, Moran C, Meng C, Paul-Smith MC, Pringle IA, Pytel KM, Rodriguez-Martinez A, Schmidt AC, Stevenson BJ, Sumner-Jones SG, Toshner R, Tsugumine S, Wasowicz MW, Zhu J.

Thorax. 2017 Feb;72(2):137-147. doi: 10.1136/thoraxjnl-2016-208406. Epub 2016 Nov 16.

2.

Genetic medicines for CF: Hype versus reality.

Alton EW, Boyd AC, Davies JC, Gill DR, Griesenbach U, Harrison PT, Henig N, Higgins T, Hyde SC, Innes JA, Korman MS.

Pediatr Pulmonol. 2016 Oct;51(S44):S5-S17. doi: 10.1002/ppul.23543. Review.

3.

A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy in patients with cystic fibrosis.

Alton EWFW, Armstrong DK, Ashby D, Bayfield KJ, Bilton D, Bloomfield EV, Boyd AC, Brand J, Buchan R, Calcedo R, Carvelli P, Chan M, Cheng SH, Collie DS, Cunningham S, Davidson HE, Davies G, Davies JC, Davies LA, Dewar MH, Doherty A, Donovan J, Dwyer NS, Elgmati HI, Featherstone RF, Gavino J, Gea-Sorli S, Geddes DM, Gibson JSR, Gill DR, Greening AP, Griesenbach U, Hansell DM, Harman K, Higgins TE, Hodges SL, Hyde SC, Hyndman L, Innes JA, Jacob J, Jones N, Keogh BF, Limberis MP, Lloyd-Evans P, Maclean AW, Manvell MC, McCormick D, McGovern M, McLachlan G, Meng C, Montero MA, Milligan H, Moyce LJ, Murray GD, Nicholson AG, Osadolor T, Parra-Leiton J, Porteous DJ, Pringle IA, Punch EK, Pytel KM, Quittner AL, Rivellini G, Saunders CJ, Scheule RK, Sheard S, Simmonds NJ, Smith K, Smith SN, Soussi N, Soussi S, Spearing EJ, Stevenson BJ, Sumner-Jones SG, Turkkila M, Ureta RP, Waller MD, Wasowicz MY, Wilson JM, Wolstenholme-Hogg P; on behalf of the UK Cystic Fibrosis Gene Therapy Consortium.

Southampton (UK): NIHR Journals Library; 2016 Jul.

4.

A Phase I/IIa Safety and Efficacy Study of Nebulized Liposome-mediated Gene Therapy for Cystic Fibrosis Supports a Multidose Trial.

Alton EW, Boyd AC, Porteous DJ, Davies G, Davies JC, Griesenbach U, Higgins TE, Gill DR, Hyde SC, Innes JA; UK Cystic Fibrosis Gene Therapy Consortium *.

Am J Respir Crit Care Med. 2015 Dec 1;192(11):1389-92. doi: 10.1164/rccm.201506-1193LE. No abstract available.

5.

Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis.

Elborn JS, Bell SC, Madge SL, Burgel PR, Castellani C, Conway S, De Rijcke K, Dembski B, Drevinek P, Heijerman HG, Innes JA, Lindblad A, Marshall B, Olesen HV, Reimann AL, Solé A, Viviani L, Wagner TO, Welte T, Blasi F.

Eur Respir J. 2016 Feb;47(2):420-8. doi: 10.1183/13993003.00592-2015. Epub 2015 Oct 9.

6.

Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial.

Alton EWFW, Armstrong DK, Ashby D, Bayfield KJ, Bilton D, Bloomfield EV, Boyd AC, Brand J, Buchan R, Calcedo R, Carvelli P, Chan M, Cheng SH, Collie DDS, Cunningham S, Davidson HE, Davies G, Davies JC, Davies LA, Dewar MH, Doherty A, Donovan J, Dwyer NS, Elgmati HI, Featherstone RF, Gavino J, Gea-Sorli S, Geddes DM, Gibson JSR, Gill DR, Greening AP, Griesenbach U, Hansell DM, Harman K, Higgins TE, Hodges SL, Hyde SC, Hyndman L, Innes JA, Jacob J, Jones N, Keogh BF, Limberis MP, Lloyd-Evans P, Maclean AW, Manvell MC, McCormick D, McGovern M, McLachlan G, Meng C, Montero MA, Milligan H, Moyce LJ, Murray GD, Nicholson AG, Osadolor T, Parra-Leiton J, Porteous DJ, Pringle IA, Punch EK, Pytel KM, Quittner AL, Rivellini G, Saunders CJ, Scheule RK, Sheard S, Simmonds NJ, Smith K, Smith SN, Soussi N, Soussi S, Spearing EJ, Stevenson BJ, Sumner-Jones SG, Turkkila M, Ureta RP, Waller MD, Wasowicz MY, Wilson JM, Wolstenholme-Hogg P; UK Cystic Fibrosis Gene Therapy Consortium.

Lancet Respir Med. 2015 Sep;3(9):684-691. doi: 10.1016/S2213-2600(15)00245-3. Epub 2015 Jul 3. Erratum in: Lancet Respir Med. 2015 Sep;3(9):e33.

7.

The prospective evaluation of the TB strain typing service in England: a mixed methods study.

Mears J, Vynnycky E, Lord J, Borgdorff MW, Cohen T, Crisp D, Innes JA, Lilley M, Maguire H, McHugh TD, Woltmann G, Abubakar I, Sonnenberg P.

Thorax. 2016 Aug;71(8):734-41. doi: 10.1136/thoraxjnl-2014-206480. Epub 2015 Apr 16.

PMID:
25882538
8.

Measurement of serum calprotectin in stable patients predicts exacerbation and lung function decline in cystic fibrosis.

Reid PA, McAllister DA, Boyd AC, Innes JA, Porteous D, Greening AP, Gray RD.

Am J Respir Crit Care Med. 2015 Jan 15;191(2):233-6. doi: 10.1164/rccm.201407-1365LE. No abstract available.

9.

Prospective evaluation of a complex public health intervention: lessons from an initial and follow-up cross-sectional survey of the tuberculosis strain typing service in England.

Mears J, Abubakar I, Crisp D, Maguire H, Innes JA, Lilley M, Lord J, Cohen T, Borgdorff MW, Vynnycky E, McHugh TD, Sonnenberg P.

BMC Public Health. 2014 Oct 2;14:1023. doi: 10.1186/1471-2458-14-1023.

10.

Lung clearance index: evidence for use in clinical trials in cystic fibrosis.

Kent L, Reix P, Innes JA, Zielen S, Le Bourgeois M, Braggion C, Lever S, Arets HG, Brownlee K, Bradley JM, Bayfield K, O'Neill K, Savi D, Bilton D, Lindblad A, Davies JC, Sermet I, De Boeck K; European Cystic Fibrosis Society Clinical Trial Network (ECFS-CTN) Standardisation Committee.

J Cyst Fibros. 2014 Mar;13(2):123-38. doi: 10.1016/j.jcf.2013.09.005. Epub 2013 Dec 5. Review.

11.

Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung.

Alton EW, Boyd AC, Cheng SH, Davies JC, Davies LA, Dayan A, Gill DR, Griesenbach U, Higgins T, Hyde SC, Innes JA, McLachlan G, Porteous D, Pringle I, Scheule RK, Sumner-Jones S.

Gene Ther. 2014 Jan;21(1):89-95. doi: 10.1038/gt.2013.61. Epub 2013 Nov 7.

PMID:
24196086
12.

The safety profile of a cationic lipid-mediated cystic fibrosis gene transfer agent following repeated monthly aerosol administration to sheep.

Alton EW, Baker A, Baker E, Boyd AC, Cheng SH, Coles RL, Collie DD, Davidson H, Davies JC, Gill DR, Gordon C, Griesenbach U, Higgins T, Hyde SC, Innes JA, McCormick D, McGovern M, McLachlan G, Porteous DJ, Pringle I, Scheule RK, Shaw DJ, Smith S, Sumner-Jones SG, Tennant P, Vrettou C.

Biomaterials. 2013 Dec;34(38):10267-77. doi: 10.1016/j.biomaterials.2013.09.023. Epub 2013 Oct 3.

PMID:
24090839
13.

Self-reactive CFTR T cells in humans: implications for gene therapy.

Calcedo R, Griesenbach U, Dorgan DJ, Soussi S, Boyd AC, Davies JC, Higgins TE, Hyde SC, Gill DR, Innes JA, Porteous DJ, Alton EW, Wilson JM, Limberis MP.

Hum Gene Ther Clin Dev. 2013 Sep;24(3):108-15. doi: 10.1089/humc.2012.249. Epub 2013 Jul 19.

14.

Forced expiratory volume in one second predicts length of stay and in-hospital mortality in patients undergoing cardiac surgery: a retrospective cohort study.

McAllister DA, Wild SH, MacLay JD, Robson A, Newby DE, MacNee W, Innes JA, Zamvar V, Mills NL.

PLoS One. 2013 May 28;8(5):e64565. doi: 10.1371/journal.pone.0064565. Print 2013.

15.

A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis.

Alton EW, Boyd AC, Cheng SH, Cunningham S, Davies JC, Gill DR, Griesenbach U, Higgins T, Hyde SC, Innes JA, Murray GD, Porteous DJ.

Thorax. 2013 Nov;68(11):1075-7. doi: 10.1136/thoraxjnl-2013-203309. Epub 2013 Mar 22.

PMID:
23525080
16.

Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation.

Horsley AR, Davies JC, Gray RD, Macleod KA, Donovan J, Aziz ZA, Bell NJ, Rainer M, Mt-Isa S, Voase N, Dewar MH, Saunders C, Gibson JS, Parra-Leiton J, Larsen MD, Jeswiet S, Soussi S, Bakar Y, Meister MG, Tyler P, Doherty A, Hansell DM, Ashby D, Hyde SC, Gill DR, Greening AP, Porteous DJ, Innes JA, Boyd AC, Griesenbach U, Cunningham S, Alton EW.

Thorax. 2013 Jun;68(6):532-9. doi: 10.1136/thoraxjnl-2012-202538. Epub 2013 Feb 9.

17.

Assessment of F/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy.

Griesenbach U, Inoue M, Meng C, Farley R, Chan M, Newman NK, Brum A, You J, Kerton A, Shoemark A, Boyd AC, Davies JC, Higgins TE, Gill DR, Hyde SC, Innes JA, Porteous DJ, Hasegawa M, Alton EW.

Am J Respir Crit Care Med. 2012 Nov 1;186(9):846-56. doi: 10.1164/rccm.201206-1056OC. Epub 2012 Sep 6.

18.

Managing passengers with stable respiratory disease planning air travel: British Thoracic Society recommendations.

Ahmedzai S, Balfour-Lynn IM, Bewick T, Buchdahl R, Coker RK, Cummin AR, Gradwell DP, Howard L, Innes JA, Johnson AO, Lim E, Lim WS, McKinlay KP, Partridge MR, Popplestone M, Pozniak A, Robson A, Shovlin CL, Shrikrishna D, Simonds A, Tait P, Thomas M; British Thoracic Society Standards of Care Committee.

Thorax. 2011 Sep;66 Suppl 1:i1-30. doi: 10.1136/thoraxjnl-2011-200295. No abstract available.

PMID:
21856702
19.

Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung.

McLachlan G, Davidson H, Holder E, Davies LA, Pringle IA, Sumner-Jones SG, Baker A, Tennant P, Gordon C, Vrettou C, Blundell R, Hyndman L, Stevenson B, Wilson A, Doherty A, Shaw DJ, Coles RL, Painter H, Cheng SH, Scheule RK, Davies JC, Innes JA, Hyde SC, Griesenbach U, Alton EW, Boyd AC, Porteous DJ, Gill DR, Collie DD.

Gene Ther. 2011 Oct;18(10):996-1005. doi: 10.1038/gt.2011.55. Epub 2011 Apr 21.

PMID:
21512505
20.

Pneumothorax in cystic fibrosis: prevalence and outcomes in Scotland.

MacDuff A, Tweedie J, McIntosh L, Innes JA.

J Cyst Fibros. 2010 Jul;9(4):246-9. doi: 10.1016/j.jcf.2010.04.005. Epub 2010 May 23.

21.

Sputum and serum calprotectin are useful biomarkers during CF exacerbation.

Gray RD, Imrie M, Boyd AC, Porteous D, Innes JA, Greening AP.

J Cyst Fibros. 2010 May;9(3):193-8. doi: 10.1016/j.jcf.2010.01.005. Epub 2010 Mar 17.

22.

Sputum trace metals are biomarkers of inflammatory and suppurative lung disease.

Gray RD, Duncan A, Noble D, Imrie M, O'Reilly DS, Innes JA, Porteous DJ, Greening AP, Boyd AC.

Chest. 2010 Mar;137(3):635-41. doi: 10.1378/chest.09-1047. Epub 2009 Oct 3.

PMID:
19801580
23.

Frequencies of region of difference 1 antigen-specific but not purified protein derivative-specific gamma interferon-secreting T cells correlate with the presence of tuberculosis disease but do not distinguish recent from remote latent infections.

Hinks TS, Dosanjh DP, Innes JA, Pasvol G, Hackforth S, Varia H, Millington KA, Liu XQ, Bakir M, Soysal A, Davidson RN, Gunatheesan R, Lalvani A.

Infect Immun. 2009 Dec;77(12):5486-95. doi: 10.1128/IAI.01436-08. Epub 2009 Sep 14.

24.

Apolipoprotein E-epsilon2 confers risk of pulmonary tuberculosis in women from the Indian subcontinent--a preliminary study.

Wozniak MA, Maude RJ, Innes JA, Hawkey PM, Itzhaki RF.

J Infect. 2009 Sep;59(3):219-22. doi: 10.1016/j.jinf.2009.07.003. Epub 2009 Jul 8. No abstract available.

PMID:
19631387
25.

Ventilation heterogeneity in children with well controlled asthma with normal spirometry indicates residual airways disease.

Macleod KA, Horsley AR, Bell NJ, Greening AP, Innes JA, Cunningham S.

Thorax. 2009 Jan;64(1):33-7. doi: 10.1136/thx.2007.095018. Epub 2008 Aug 4.

PMID:
18678703
26.

Effects of cystic fibrosis lung disease on gas mixing indices derived from alveolar slope analysis.

Horsley AR, Macleod KA, Robson AG, Lenney J, Bell NJ, Cunningham S, Greening AP, Gustafsson PM, Innes JA.

Respir Physiol Neurobiol. 2008 Aug 31;162(3):197-203. doi: 10.1016/j.resp.2008.06.014. Epub 2008 Jun 25.

PMID:
18625345
27.

Using laboratory measurements to predict in-flight desaturation in respiratory patients: are current guidelines appropriate?

Robson AG, Lenney J, Innes JA.

Respir Med. 2008 Nov;102(11):1592-7. doi: 10.1016/j.rmed.2008.05.005. Epub 2008 Jul 9.

28.

Sputum proteomics in inflammatory and suppurative respiratory diseases.

Gray RD, MacGregor G, Noble D, Imrie M, Dewar M, Boyd AC, Innes JA, Porteous DJ, Greening AP.

Am J Respir Crit Care Med. 2008 Sep 1;178(5):444-52. doi: 10.1164/rccm.200703-409OC. Epub 2008 Jun 19.

29.

Review article: Adenosine use in the emergency department.

Innes JA.

Emerg Med Australas. 2008 Jun;20(3):209-15. doi: 10.1111/j.1742-6723.2008.01100.x. Review.

PMID:
18549383
30.

Improved diagnostic evaluation of suspected tuberculosis.

Dosanjh DP, Hinks TS, Innes JA, Deeks JJ, Pasvol G, Hackforth S, Varia H, Millington KA, Gunatheesan R, Guyot-Revol V, Lalvani A.

Ann Intern Med. 2008 Mar 4;148(5):325-36. Erratum in: Ann Intern Med.2008 Apr 15;148(8):635.

31.

Biomarkers for cystic fibrosis lung disease: application of SELDI-TOF mass spectrometry to BAL fluid.

MacGregor G, Gray RD, Hilliard TN, Imrie M, Boyd AC, Alton EW, Bush A, Davies JC, Innes JA, Porteous DJ, Greening AP.

J Cyst Fibros. 2008 Sep;7(5):352-8. doi: 10.1016/j.jcf.2007.12.005. Epub 2008 Feb 1.

32.

Lung clearance index in CF: a sensitive marker of lung disease severity.

Davies JC, Cunningham S, Alton EW, Innes JA.

Thorax. 2008 Feb;63(2):96-7. doi: 10.1136/thx.2007.082768. No abstract available.

PMID:
18234652
33.

Intravenous magnesium sulphate provides no additive benefit to standard management in acute asthma.

Bradshaw TA, Matusiewicz SP, Crompton GK, Innes JA, Greening AP.

Respir Med. 2008 Jan;102(1):143-9. Epub 2007 Sep 14.

34.

Lung clearance index is a sensitive, repeatable and practical measure of airways disease in adults with cystic fibrosis.

Horsley AR, Gustafsson PM, Macleod KA, Saunders C, Greening AP, Porteous DJ, Davies JC, Cunningham S, Alton EW, Innes JA.

Thorax. 2008 Feb;63(2):135-40. Epub 2007 Aug 3.

PMID:
17675315
35.

Hypersensitivity pneumonitis associated with leflunomide therapy.

Martin N, Innes JA, Lambert CM, Turnbull CM, Wallace WA.

J Rheumatol. 2007 Sep;34(9):1934-7. Epub 2007 Jul 1.

PMID:
17611977
36.

Cluster of human tuberculosis caused by Mycobacterium bovis: evidence for person-to-person transmission in the UK.

Evans JT, Smith EG, Banerjee A, Smith RM, Dale J, Innes JA, Hunt D, Tweddell A, Wood A, Anderson C, Hewinson RG, Smith NH, Hawkey PM, Sonnenberg P.

Lancet. 2007 Apr 14;369(9569):1270-1276. doi: 10.1016/S0140-6736(07)60598-4.

PMID:
17434402
37.

Dynamic relationship between IFN-gamma and IL-2 profile of Mycobacterium tuberculosis-specific T cells and antigen load.

Millington KA, Innes JA, Hackforth S, Hinks TS, Deeks JJ, Dosanjh DP, Guyot-Revol V, Gunatheesan R, Klenerman P, Lalvani A.

J Immunol. 2007 Apr 15;178(8):5217-26.

38.

Respiratory heat and moisture loss is associated with eosinophilic inflammation in asthma.

Noble DD, McCafferty JB, Greening AP, Innes JA.

Eur Respir J. 2007 Apr;29(4):676-81. Epub 2006 Nov 29.

39.

Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis.

Guyot-Revol V, Innes JA, Hackforth S, Hinks T, Lalvani A.

Am J Respir Crit Care Med. 2006 Apr 1;173(7):803-10. Epub 2005 Dec 9.

PMID:
16339919
40.

MRSA in the community.

Chapman AL, Greig JM, Innes JA.

N Engl J Med. 2005 Aug 4;353(5):530-2; author reply 530-2. No abstract available.

PMID:
16079384
41.

Seasonality of presentation of imported Plasmodium vivax malaria in Birmingham, UK.

Venkatesan P, Dedicoat M, Innes JA, Ellis CJ.

Trans R Soc Trop Med Hyg. 2003 Sep-Oct;97(5):550.

PMID:
15307423
42.
43.

Chest physicians' and microbiologists' awareness and demand for drug monitoring in the treatment of TB.

Pooransingh S, Smith EG, Innes JA.

Commun Dis Public Health. 2003 Dec;6(4):317-9.

PMID:
15067858
44.

Exhaled breath temperature in airways disease.

McCafferty JB, Innes JA.

Eur Respir J. 2003 Aug;22(2):393-4; author reply 394-5. No abstract available.

45.

Airways in cystic fibrosis are acidified: detection by exhaled breath condensate.

Tate S, MacGregor G, Davis M, Innes JA, Greening AP.

Thorax. 2002 Nov;57(11):926-9.

46.

Moving from CFC aerosol to HFA aerosol or dry powder inhalers: what do patients think?

Hartung TK, Allbutt H, Dewar M, Innes JA, Crompton GK.

Respiration. 2002;69(4):314-9.

PMID:
12169743
47.
48.

Atopy influences exhaled nitric oxide levels in adult asthmatics.

Ho LP, Wood FT, Robson A, Innes JA, Greening AP.

Chest. 2000 Nov;118(5):1327-31.

PMID:
11083682
49.

Laboratory assessment of fitness to fly in patients with lung disease: a practical approach.

Robson AG, Hartung TK, Innes JA.

Eur Respir J. 2000 Aug;16(2):214-9.

50.

Measure and interpretation of CF gene therapy trial results.

Alton E, Geddes D, Gill D, Greening A, Higgins C, Hyde S, Innes JA, Porteous D, Stern M.

Mol Ther. 2000 Jul;2(1):3-4. No abstract available.

Supplemental Content

Loading ...
Support Center